Clinical Trials Browser

Interventional × Lung Neoplasms × durvalumab × Clear all

NCT05450692 2026-04-16

LATIFY

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07288034 2026-04-15

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06498635 2026-04-14

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04092283 2026-04-13

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05198830 2026-04-13

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Recruiting

Adenocarcinoma of Lung, Lung Neoplasms

NCT06287775 2026-04-13

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Phase 1/2 Recruiting

Lung Neoplasms

NCT06732401 2026-04-13

CLEAR

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07339059 2026-04-09

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05624996 2026-04-03

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT03589547 2026-04-02

358

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT06606847 2026-03-18

LADOGA

Phase 2 Active not recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05061550 2026-03-11

NeoCOAST-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05632809 2026-03-11

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Phase 2 Recruiting

Lung Neoplasms

NCT05941897 2026-03-05

LOTOS

Phase 2 Active not recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04716946 2026-03-04

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05068232 2026-03-04

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase 1 Active not recruiting

Bites and Stings, Lung Neoplasms

NCT04602533 2026-02-27

Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)

Phase 2 Active not recruiting

Lung Neoplasms

NCT04892953 2026-02-19

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Phase 2 Recruiting

Lung Neoplasms

NCT05403723 2026-02-19

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Phase 1 Suspended

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05443971 2026-02-06

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03141359 2026-02-05

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Phase 2 Active not recruiting

61 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03833154 2026-01-26

PACIFIC-4

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04748419 2026-01-22

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05374603 2026-01-21

SOUND

Phase 2 Active not recruiting

Lung Neoplasms

NCT04728230 2025-12-18

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

Phase 1/2 Active not recruiting

Lung Neoplasms

NCT05886439 2025-12-08

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Phase 1/2 Recruiting

Lung Neoplasms

NCT03999710 2025-11-28

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Recurrence

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 3 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02572843 2025-10-28

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

68 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04108026 2025-10-03

SAVIMMUNE

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04472949 2025-10-01

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Phase 2 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03801902 2025-09-23

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Phase 1 Completed

26 enrolled 17 charts

Lung Neoplasms

NCT04105270 2025-09-11

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Phase 2 Recruiting

Adenocarcinoma of Lung, Lung Neoplasms

NCT04380636 2025-08-17

MK-7339-012

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03620669 2025-08-15

1st Line Durvalumab in PS 2 NSCLC Patients

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05136846 2025-06-04

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Phase 1 Recruiting

Lung Neoplasms

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03212469 2025-05-08

ABIMMUNE

Phase 1/2 Completed

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Lung Neoplasms

NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Phase 2 Active not recruiting

GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05358691 2025-04-16

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Phase 1 Withdrawn

Lung Neoplasms

NCT04003246 2025-03-21

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

Phase 2 Completed

10 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04230408 2025-02-11

PACIFIC BRAZIL

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04364048 2024-12-20

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Phase 2 Terminated

10 enrolled 10 charts

Lung Neoplasms

NCT04944173 2024-09-03

SCION

Phase 2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT04348292 2024-08-22

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

Phase 1 Terminated

3 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms